Search company, investor...
Search
Imascap company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

imascap.com

Stage

Acquired | Acquired

Valuation

$0000 

About Imascap

Imascap is a developer of surgical planning software. The software allows the surgeon to automatically conceive a surgical guide adapted particularly to the patient anatomy, which permits the surgeon to implant the prosthesis in a position that closely matched the software plan.

Imascap Headquarters Location

65, place Nicolas Copernic

Plouzane, 29280,

France

+33-2-90-26-21-70

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Imascap

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Imascap is included in 1 Expert Collection, including Digital Health.

D

Digital Health

13,113 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Imascap Patents

Imascap has filed 13 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Orthopedic surgical procedures
  • Prosthetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/13/2021

8/2/2022

Orthopedic surgical procedures, Prosthetics, Implants (medicine), Surgery, Shoulder

Grant

Application Date

4/13/2021

Grant Date

8/2/2022

Title

Related Topics

Orthopedic surgical procedures, Prosthetics, Implants (medicine), Surgery, Shoulder

Status

Grant

Latest Imascap News

Wright Medical débourse 75 M€ pour s’offrir Imascap

Jan 9, 2018

Wright Medical débourse 75 M€ pour s’offrir Imascap Par WS | 09/01/2018 | 12:41 2017 aura été une année faste pour les medtechs tricolores, qui suscitent de plus en plus la convoitise des gros groupes étrangers. Après AAA (racheté pour 3,9 Md$ par Novartis) et Vexim (162 M€ offerts par Stryker Corporation) en octobre, c’est la jeune pousse brestoise Imascap qui a bouclé l’année 2017 en fanfare : elle s’est précisément vue valorisée 75,1 M€ par l’américain Wright Medical. Un prix qui sera payé en partie en titres, à hauteur de 13,2 M€, et qui comprend 22,2 M€ d’earn-outs conditionnés aux futurs développements. Née en 2009 à l’initiative de l’ingénieur-mathématicien Jean Chaoui, associé à plusieurs chirurgiens français et américains, Imascap est présentée par l’acquéreur comme le leader mondial des solutions logicielles pré-opératives pour la chirurgie orthopédique de l’épaule (imagerie médicale, reconstitution 3D et impression de l’instrumentation médicale en 3D). Baptisée Glenosys, sa solution est notamment utilisée par Wright Medical depuis 2016. Actuellement, elle dégage déjà près de 1 M€ de revenus. Imascap travaille à l’adaptation de sa technologie aux prothèses de genoux. Elle œuvre aussi en association avec le CHRU de Brest à la conception de prothèses connectées.

  • Where is Imascap's headquarters?

    Imascap's headquarters is located at 65, place Nicolas Copernic, Plouzane.

  • What is Imascap's latest funding round?

    Imascap's latest funding round is Acquired.

  • Who are the investors of Imascap?

    Investors of Imascap include Wright Medical Group.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.